An analyst at Merriman Curhan Ford believes that Biogen (Nasdaq: BIIB) needs to boost its bid for Facet Biotech (Nasdaq ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE